Compare DFDV & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DFDV | ACOG |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | Canada |
| Employees | 16 | 57 |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 110.4M |
| IPO Year | N/A | N/A |
| Metric | DFDV | ACOG |
|---|---|---|
| Price | $3.01 | $6.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $45.00 | $16.00 |
| AVG Volume (30 Days) | ★ 857.9K | 31.2K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.58 | $139.22 |
| Revenue Next Year | $23.65 | $134.48 |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.93 | $4.50 |
| 52 Week High | $33.75 | $10.88 |
| Indicator | DFDV | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 28.72 | 47.63 |
| Support Level | N/A | $5.70 |
| Resistance Level | $5.22 | $6.34 |
| Average True Range (ATR) | 0.32 | 0.32 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 2.25 | 48.28 |
DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.